Despite continuous efforts to control malaria, outside Africa, more malaria cases are caused by *Plasmodium vivax*, resulting in a daunting morbidity and economic burden for many countries across Asia and the Americas, especially in rural areas[@B1]. Nowadays, *P. vivax* malaria transmission has decreased during the last decade, although its distribution persists and is heterogeneous in different areas[@B2].

Among Amazon countries, Brazil has the highest proportion of malaria cases (56%)[@B3]. In Brazil, gradual decreases from 2006 until 2012 have been observed. Nevertheless, *P. vivax* now accounts for more than 84% of clinical malaria cases annually reported in the Amazon region[@B4]. The circumsporozoite protein (CS) of the infective sporozoite is considered to be a major target for the development of recombinant malaria vaccine[@B5] and, this protein can be evidenced in the process of sporozoite maturation and salivary invasion in the vector as well as in human liver cells[@B6] ^,^ [@B7]. By serological and/or molecular approaches, different authors have evaluated the occurrence of *P. vivax* variants (VK210, VK247 and *P. vivax*-like) in endemic areas of the Amazon region[@B8] ^-^ [@B11]. Furthermore, the VK210 and VK247 were detected in *An. aquasalis* and *An. darlingi* in endemic areas of *Pará* State, Brazil^12^.

Border areas between countries are often characterized by intense cross-border population flows[@B13]. The city of *Oiapoque* lies on the border between French Guiana and the Brazilian State of *Amapá*, where there is a well-documented and intense population flux with the French municipality of Saint Georges[@B14]. In French Guiana malaria is endemic and distributed along the *Maroni* and *Oiapoque* rivers, whereas the coastal area bordering the Atlantic Ocean has almost no malaria transmission[@B14]. A serological study in seven locations of the French Guiana (Cayenne, Camopi, Maripa Soula, Saint Laurent du Maroni, Gran Santi and Sinnamary) suggested that the three variant forms of *P. vivax* are circulating in these areas[@B15].

*P. vivax* CS genotypes VK210 and VK247 have a worldwide distribution and have been identified in several studies. However, the *P. vivax-like* genotype has been only detected in Papua New Guinea, Brazil, Indonesia and Madagascar[@B16] ^,^ [@B17]. In Brazil, the presence of three variant genotypes was detected in samples obtained from indigenous populations and other communities of the Amazon region. Furthermore, there is evidence from Mexico[@B2] and Brazil[@B12] that VK210 and VK247 have differential infectivity rates in local vectors. Here we discuss *P. vivax* distribution pattern in the town of *Oiapoque, Amapá* State using the CS gene as a marker.

A subset of 91 patients was analyzed out of 103 individuals previously evaluated by Gomes *et al*.[@B18]. The peripheral blood samples, which had been kept at -70 °C, were from *P. vivax* carriers who lived in *Oiapoque, Amapá* State, a Brazilian malaria-endemic area ([Fig. 1](#f1){ref-type="fig"}). The study took place from August to December of 2011 and was conducted by the staff of the Central Public Health Laboratory (LACEN) of the *Amapá* State. The patients who were enrolled in this study signed the written informed consent and fulfilled the following criteria: both genders, aged 16-60 years, they sought medical assistance due to clinical malaria symptoms, and had a positive malaria diagnosis by thick blood film or molecular techniques. Of the evaluated patients, for 64 individuals (70.33%) the infection site was the municipality of *Oiapoque* and for 27 patients (29.67%) it was French Guiana.

Fig. 1Map of the Brazilian Amazon region, showing the locations of the two populations from which isolates of *Plasmodium vivax* studied here were obtained: French Guiana and *Oiapoque*, Brazil.

The DNA was extracted from frozen pellets of infected erythrocytes using the Easy-DNA(tm) Kit (Invitrogen, Carlsbad, CA, USA), according to the manufacturer recommendations. The CS *P. vivax* genotypes were assessed using PCR/RFLP as previously described by Cassiano *et al*.[@B19]. Briefly, a reaction mix with a final volume of 25 µL containing *P. vivax* DNA (1.5 µL), 1 X PCR buffer (20 mM Tris-HCl pH 8.4, 50 mM KCl), 1.6 mM MgCl, 0.2 mM of each dNTP, 0.2 µM of each primer (5\'-AGGCAGAGGACTTGGTGAGA-3\' and 5\'-CCACAGGTTACACTGCATGG-3\') and 1 U of Taq Platinum. The reaction was performed in a thermocycler (DNA MasterCycler, Eppendorf, Madison, WI, USA) as follows: an initial cycle of 94 °C for 15 min, followed by 30 cycles of 94 °C for 1 min, 58 °C for 1 min and 72 °C for 1 min, with a final extension at 72 °C for 10 min. As a positive control, three plasmids were used, containing a gene insert of the repeated portion of the CSP amplification product from VK210, VK247 and *P. vivax*-like variants (BlueScript, Stratagene, La Jolla, USA). As the negative control of the reaction, sterile water was used. The RFLP (Restriction Fragment Length Polymorphism) reaction was performed in a final volume of 20 µL: 10 U of the restriction enzyme AluI (Invitrogen, USA), 2 µL of the reaction buffer, 10 µL of the PCR product and 7 µL of sterile DNAse-free water. Reactions were performed in a water bath at 37 °C overnight.

Analyses were performed using the R statistical software, version 2.4.1 (The R Foundation for Statistical Computing, Vienna, Austria [\[http://www.r-project.org](http://www.r-project.org/)\]). The distribution of *P. vivax* CSP variants between the two studied areas was evaluated by the Chi-square test or the Fisher exact test, and the level of significance was set at *p* \< 0.05.

The distribution of *P. vivax* CS genotypes and the genotypic frequencies of the 91 blood samples obtained from malaria patients are summarized in [Table 1](#t1){ref-type="table"}. The VK210 genotype was the commonest (62.64%), followed by *P. vivax*-like (2.20%) and VK247 (1.10%) in single infections. We were unable to detect all three CS genotypes simultaneously in mixed infections. However, double detections of VK210 plus VK247 (26.37%) and VK210 plus *P. vivax*-like (7.69%) were recorded. There were no statistically significant differences for *P. vivax* CS genotypes and the site of infection (Chi- square, *p* value = 0.1963). The parasitaemia on the thick blood films ranged from 200 to 36,000 parasites/mm^3^ (geometric mean + SD: 1,167.86 ± 3.32 parasites/mm^3)^. The geometric means of parasitaemias were 1,323 parasites/mm^3^ (1,001- 1,750) for VK210; 1,205 parasites/mm^3^ (744- 1,951) for the VK210 + VK247 and 750 parasites/mm^3^ (295- 1,890) for VK210 + *P. vivax*-like infections. There were no statistically significant differences of the geometric mean of parasite density among the different genotypes detected ([Table 1](#t1){ref-type="table"}).

Table 1Distribution of *P. vivax* variants diagnosed in *Oiapoque*, Brazil, bordering French GuianaSite of Infection\*Single typesMixed typesVK210VK247*P. vivax*-likeVK210 + VK247VK247 + *P. vivax*-likeVK210 + *P. vivax*-likeVK210 + VK247 + *P. vivax*-likeTotalFrench Guiana13 (14.28%)01 (1.10%)10 (10.98%)03 (3.30%)027 (29.67%)*Oiapoque*44 (48.36%)1 (1.10%)1 (1.10%)14 (15.38%)04 4.39%)064 (70.33%)Total57 (62.64%)1 (1.10%)2 (2.20%)24 (26.37%)07 (7.69%)091[^2]

Epidemiological and genetic studies performed in malaria endemic areas of frontier malaria in Brazil could provide valuable information on parasite transmission and dispersion. The genetic diversity of the CS gene has been useful in molecular epidemiological studies, understanding transmission, dynamics and evolutionary relationships[@B20]. Moreover, biological and genetic characteristics of the parasite, the host immunity and local vectors may influence the different patterns of demographic expansion, which are also modulated by eco-epidemiological conditions. However, the human effect can become a factor to reduce the risk of malaria, without necessarily modifying the environment[@B3] ^,^ [@B21].

Parasitic sampling in *Oiapoque* was performed, and followed a similar gradual pattern of *P. vivax* CS genotypes observed in others area of the Brazilian Amazon region. The three genotypes were found as single and mixed double infections, with VK210 and VK247 more frequently detected in mixed infections[@B10]. Interestingly, in French Guiana Volney *et al*.[@B15]performed a seroepidemiological study on malaria and found positive reactions with all *P. vivax* CS peptides in malaria patients from the *Maroni, Oiapoque* and coastal areas. Antibodies against VK210, VK247 and *P. vivax*- like were used. Our results suggest that this may be a common feature of frontier malaria. Thus, the same genotypes circulating in French Guiana were also found in the municipality of *Oiapoque* in Brazil. Moreover, the detection of VK210 subtypes circulating in the municipality of *Oiapoque* needs to be considered. In our research, some samples diagnosed as VK210 showed a nonspecific fragment in the RFLP gel. Recently, six different VK210 subtypes (VK210a, VK210b, VK210c, VK210d, VK210e the VK210f) were identified in isolates of *P. vivax* from Nicaragua and Mexico. The VK210a subtype was detected in both countries and was the most frequent. VK210f, was the less frequent, and has only been found in Nicaragua[@B21]. Unfortunately, the sequencing of these samples was not performed, which is a limitation that we acknowledge. Molecular investigations are currently being conducted to understand the role of VK210 subtypes in malaria epidemiology in bordering French Guiana.

This pattern of CS genotypes distribution at the border between Brazil and French Guiana, can bring serious implications to the strategies for effective malaria control. First, approximately 40% of *P. vivax* malaria cases detected in *Oiapoque* are from French Guiana[@B4]. From another perspective, the *P. vivax* treatment prescription used in Brazil is not the same applied in French Guiana. In Brazil the standard treatment recommended by Brazilian Ministry Health are chloroquine 25 mg/kg for three days (10 mg/kg on day 1 and 7.5 mg/kg on days 2 and 3), plus primaquine 0.50 mg/kg for 7 days. In French Guiana, when the diagnosis is confirmed, the patient has already received an unsupervised three-day treatment with chloroquine (25 mg/Kg). To receive a primaquine prescription, the individual requires a G6PD-deficiency test performed in Cayenne and a nominative temporary use authorization from the State drug authority. Thus, this procedure causes delay in the administration of primaquine. Consequently, approximately half of the population was presented *P. vivax* relapses[@B14]. Moreover, the periodicity of vivax malaria relapses may be explained by the activation of latent hypnozoites by subsequent infections with *P. falciparum.* Evidence from a simultaneous typhoid and malaria epidemic suggest that typhoid fever might activate *P. vivax* hypnozoites[@B22] ^,^ [@B23]. However, previous reports suggest that in mixed infections, one *Plasmodium* species may suppress the blood-stage density of another species[@B24] ^,^ [@B25]. Thus, species interactions may cause alterations in the typical clinical manifestation of infections caused by only one species, therefore additional investigations are necessary in order to clarify the role of mixed-infections on disease severity and also in the parasite transmission dynamics, considering that events taking place in French Guiana can influence the transmission and spread of the parasite on the Brazilian side.

In conclusion, a large proportion of all malaria cases in South America occur in the Brazilian Amazon region. The emergence of epidemic and endemic foci is affected by colonization of different areas by different human groups. However, it remains unclear whether parasites are commonly spread from one area to another by migrants or whether they emerge mainly from local endemic populations[@B26]. The same CS genotypes circulating in French Guiana are found in the municipality of *Oiapoque* in Brazil. These findings suggest that it may occur via the dispersion of parasite populations between the two countries. Most likely, this distribution is associated with prolonged and/or more complex transmission patterns of these genotypes in Brazil, bordering French Guiana. Furthermore, studies based in CSP should consider these effects to obtain a protective vaccine.

We thank all the subjects who participated in the study, as well as the health teams and coordination group from the *Oiapoque* District. We thank the following people for assistance in obtaining samples: Manoel do Carmo Barbosa da Cruz and to Valmir Corrêa and Corrêa. We thank Valéria Fraga and Luciana Moran for their technical support.

FINANCIAL SUPPORT The work reported in this manuscript was funded by the National Scientific and Technological Development in the Research Program for Health System Unique (CNPq PPSUS Public Notice No. 00077/2008/MCT/CNPq/SETEC, Process No. 35.000.162/2009) , and Government of the State of *Amapá*, and also, Central Public Health Laboratory (LACEN) of *Amapá*.

[^1]: CONFLICT OF INTEREST The authors declare no conflicts of interest.

[^2]: \*Chi-Square, *p* = 0.1963
